REAL AD Study Leader in Expressen: Research Advances Give Hope for Future Alzheimer’s Patients
September 22, 2025
In connection with World Alzheimer’s Month, Hjärnfonden has launched a major campaign to raise awareness about Alzheimer’s disease. In an article in Expressen, the REAL AD study leader, Professor Michael Schöll, discusses the latest research advances, new diagnostic methods, and the development of medications that could give hope to future patients.
While the REAL AD study is ongoing, new medications for Alzheimer’s disease are being developed, including one that was recently approved in Europe. This is particularly significant because early diagnosis, which the study is testing, is a prerequisite for these new treatments to provide real benefit to patients. Michael Schöll also emphasizes the importance of external funding, including support from Hjärnfonden, to carry out the study and advance the research.
The goal is that these new diagnostic methods can eventually be implemented in healthcare in a simple and cost-effective way, allowing more patients to access the right treatment in time. With these research advances, there is hope for an attitudinal shift that will help new findings be translated into practice more quickly.
Today, approximately 150,000 people in Sweden live with dementia, two-thirds of whom have Alzheimer’s disease. The number is expected to double by 2050, underscoring the importance of continued research and support.
Read the full article here: https://kampanj.expressen.se/hjarnfonden/forskarframgangar-skapar-hopp-for-framtida-alzheimerpatienter/